Medtronic PLC (MDT) Stock Analysis
Verdict: BUY
MiniMed split-off and robotic/ablation innovation drive margin expansion, while 2.6x debt/EBITDA and GLP-1 headwinds test execution.
Investment score: 66/100
Analysis as of
Is Medtronic PLC stock worth reviewing? AI model thesis
The model classifies MDT as a Buy due to its attractive relative valuation (21.34x P/E vs peer 25.70x), low Beta (0.59), and catalyst-rich pipeline in cardiac ablation and robotics.
7-factor investment score
- Valuation: 68/100 (weight 20%)
- Financial Health: 72/100 (weight 15%)
- Technical Momentum: 62/100 (weight 15%)
- Earnings Quality: 70/100 (weight 15%)
- Insider Sentiment: 40/100 (weight 10%)
- Analyst Consensus: 75/100 (weight 10%)
- Risk-Adjusted Return: 70/100 (weight 15%)
Medtronic PLC opportunities and risks
What speaks for MDT
- Tax-Free MiniMed Diabetes Split-Off Unlocks Corporate Value
What speaks against MDT
- Elevated Financial Leverage Burden ($27.96B Debt / 2.60x Net Debt/EBITDA)
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| MDT | 21.5x | 3.0x | 13.6x | 66.7% | 13.9% | 5.5% |
| STE | 25.7x | 3.4x | 13.6x | 44.4% | 13.3% | 4.5% |
| TRIB | n/a | 3.4x | n/a | 38.5% | -78.9% | -2.7% |
| Peer median | 12.8x | 3.4x | n/a | 41.5% | -32.8% | 0.9% |
Frequently asked questions about Medtronic PLC (MDT)
Is MDT stock a good investment?
The cached TradeMates AI model rates Medtronic PLC as BUY with an investment score of 66/100. The model classifies MDT as a Buy due to its attractive relative valuation (21.34x P/E vs peer 25.70x), low Beta (0.59), and catalyst-rich pipeline in cardiac ablation and robotics. This is algorithmic model output, not personal investment advice.
Is MDT stock a buy?
The TradeMates model verdict for MDT is BUY with an investment score of 66/100. Treat this as a model signal to review, not a personal buy recommendation.